NASDAQ: HCWBHcw Biologics Inc Stock
$1.66+0.07 (+4.4%)
Updated Apr 18, 2024
HCWB Price
$1.66
Fair Value Price
-$0.18
Market Cap
$62.79M
52 Week Low
$0.91
52 Week High
$2.32
P/E
-2.37x
P/B
4.66x
P/S
78.55x
PEG
N/A
Dividend Yield
N/A
Revenue
$560.36k
Earnings
-$24.99M
Gross Margin
100%
Operating Margin
-4,409.89%
Profit Margin
-4,460.4%
Debt to Equity
1.12
Operating Cash Flow
-$23M
Beta
0.5
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
HCWB Overview
HCW Biologics Inc. is a preclinical stage biopharmaceutical company developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company has developed over 30 molecules using its TOBI (Tissue factOr-Based fusIon) platform. The company was incorporated in 2018 and is headquartered in Miramar, FL.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how HCWB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HCWB ($1.66) is overvalued by 1,043.74% relative to our estimate of its Fair Value price of -$0.18 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
HCWB ($1.66) is not significantly undervalued (1,043.74%) relative to our estimate of its Fair Value price of -$0.18 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
HCWB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more HCWB due diligence checks available for Premium users.
Be the first to know about important HCWB news, forecast changes, insider trades & much more!
HCWB News
Valuation
HCWB fair value
Fair Value of HCWB stock based on Discounted Cash Flow (DCF)
Price
$1.66
Fair Value
-$0.18
Undervalued by
1,043.74%
HCWB ($1.66) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
HCWB ($1.66) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
HCWB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
HCWB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.37x
Industry
15.68x
Market
41.33x
HCWB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.66x
Industry
5.76x
HCWB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HCWB's financial health
Profit margin
Revenue
$252.6k
Net Income
-$10.7M
Profit Margin
-4,227.5%
HCWB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
HCWB's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$28.5M
Liabilities
$15.1M
Debt to equity
1.12
HCWB's short-term liabilities ($8.75M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HCWB's short-term assets ($6.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HCWB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.9M
Investing
-$3.7M
Financing
-$15.3k
HCWB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HCWB vs Biotech Stocks
Hcw Biologics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.